# A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy

> **NCT05361798** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 65 (estimated)

## Conditions studied

- Cancer Of Prostate

## Interventions

- **DRUG:** PDS01ADC
- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT)

## Key facts

- **NCT ID:** NCT05361798
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-12
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05361798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05361798, "A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05361798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*